Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and RNA medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and RNA-based therapeutics.

Placeholder

Arcturus Therapeutics

  • CureVac LogoCureVac and Arcturus Therapeutics Announce Broad Strategic Collaboration to Advance Next Generation of Lipid-Mediated mRNA TherapeuticsREAD MORE
  • Synthetic GenomicsArcturus Therapeutics Announces Strategic Alliance with Synthetic Genomics, Inc. to develop self-amplifying RNA-based vaccines and therapeuticsREAD MORE
  • Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA MedicinesREAD MORE
  • Arcturus Therapeutics to Receive Up to $3 Million from Cystic Fibrosis Foundation to Advance a Novel LUNAR-Formulated mRNA CFTR TherapeuticREAD MORE
  • Takeda Pharmaceuticals logoTakeda Pharmaceuticals entered into collaboration with Arcturus Therapeutics to develop RNA-based therapeutics for the treatment of NASH.READ MORE

LUNAR®-mediated delivery of RNA into cells

LUNAR particles associate with the cell membrane of a target cell of interest and quickly enter the cell via endocytosis.

Upon entering the cytosol, the LUNAR formulations then become trapped in the endosomes.

With increased acidity as the endosome ages, a pH-mediated disruption enables release of the RNA payload following rapid biodegradation of the LUNAR components.

Once release of the RNA into the cytosol occurs, the translational machinery can interact with the RNA and processing and/or trafficking can then take place to make functional protein.

LUNAR® lipid mediated delivery enables delivery of RNA medicines.

News & Events

  • October 1, 2018

    Arcturus Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    • October 1 2018
    • 0
    read more
  • September 25, 2018

    Arcturus Therapeutics to Present at October Investor Conferences

    • September 25 2018
    • 0
    read more
  • September 21, 2018

    Arcturus Therapeutics Expands Management Team

    • September 21 2018
    • 0
    read more
  • August 29, 2018

    Arcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditor

    • September 14 2018
    • 0
    read more
  • August 28, 2018

    Arcturus Therapeutics Appoints Andrew Sassine as Interim Chief Financial Officer

    • August 28 2018
    • 0
    read more
  • August 27, 2018

    Arcturus Therapeutics to Present at Three Investor Conferences in September

    • August 27 2018
    • 0
    read more
  • July 23, 2018

    Arcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeutics

    • July 23 2018
    • 0
    read more
  • July 20, 2018

    Arcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018

    • July 20 2018
    • 0
    read more
  • July 9, 2018

    Arcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholders

    • July 9 2018
    • 0
    read more